Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.

05/13/2026, 6:00 AM • GlobeNewswire

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.

04/20/2026, 1:00 PM • GlobeNewswire

Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

Artios Pharma appointed three senior leaders to strengthen late-stage development capabilities: Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as VP of Clinical Operations, and Pablo Lee as VP of Medical Affairs. These appointments aim to accelerate the company's DDR-based oncology pipeline, particularly alnodesertib, toward potential commercialization and FDA approval.

02/16/2026, 8:00 AM • GlobeNewswire

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.

02/12/2026, 6:00 AM • GlobeNewswire

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiration in 2030, and intense competition from Jazz Pharmaceuticals' blockbuster treatments Xywav and Xyrem.

01/27/2026, 12:02 PM • The Motley Fool

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed healthcare assets and biotherapeutics pipeline.

01/27/2026, 6:00 AM • GlobeNewswire

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Jazz Pharmaceuticals announced positive Phase 3 trial results for Ziihera (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma. The triplet therapy combining Ziihera with tislelizumab and chemotherapy achieved a median overall survival of 26.4 months, the longest reported in a Phase 3 GEA trial, representing a 28% reduction in death risk. The doublet therapy also showed strong results with median OS of 24.4 months. Jazz shares rose 2.07% following the announcement.

01/07/2026, 1:12 PM • Benzinga

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.

01/06/2026, 1:34 PM • GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.

11/24/2025, 6:00 AM • GlobeNewswire

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.

11/17/2025, 12:09 PM • Benzinga

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks, a clinical-stage biotechnology company, announced participation in upcoming investor conferences and highlighted its progress in developing biotherapeutics for cancer and other diseases, including the FDA-approved zanidatamab for biliary tract cancer.

10/28/2025, 6:00 AM • GlobeNewswire

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

Alkermes agreed to acquire Avadel Pharmaceuticals for up to $20 per share, valuing the deal at $2.1 billion. The acquisition includes the narcolepsy drug Lumryz and is expected to close in Q1 2026, with potential additional payment contingent on FDA approval.

10/22/2025, 3:18 PM • Benzinga

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks will report its Q3 2025 financial results on November 6, 2025, and host a conference call to discuss financial performance and provide a corporate update.

10/16/2025, 6:00 AM • GlobeNewswire

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

The FDA approved Tecentriq and lurbinectedin as the first combination therapy for maintenance treatment of extensive-stage small cell lung cancer, reducing disease progression risk by 46% and death risk by 27% in clinical trials.

10/03/2025, 1:05 AM • GlobeNewswire

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals executives will participate in two upcoming investor conferences: Citi 20th Annual BioPharma Conference in Boston and H.C. Wainwright 27th Annual Global Investment Conference in New York, presenting and hosting investor meetings.

08/19/2025, 4:00 PM • GlobeNewswire